Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response signatureIeuan Walker, Michael A. Chapman, Ceri Bygrave et al.|medRxiv|2023Cited by 2
P-084: Bone marrow of patients post ASCT, but not chemotherapy consolidation, contains expanded T cell receptor clonotypes that are present at diagnosis: results from the Phase 2 CARDAMON studyKane Foster, Kwee Yong, Daria Galas‐Filipowicz et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 0
OAB-018: From CARDAMON to CoMMpass: a mutational signature that predicts carfilzomib-specific outcomes in myelomaIeuan Walker, Michael Chapman, Garima Khandelwal et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 0
Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in MyelomaIeuan Walker, Michael A. Chapman, Venetia D’arcy et al.|Blood|2022Cited by 0
P-390 The differentiation and expansion of T cell clonotypes in the bone marrow following ASCT: insights from the Phase 2 CARDAMON studyKane Foster, Kwee Yong, Daria Galas‐Filipowicz et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 0